Neuroendocrine Tumors
Conditions
Keywords
Peptide Receptor Radionuclide treatment
Brief summary
the investigators will follow up after patients with neuroendocrine tumors who undergo PRRT treatment and evaluate the response for treatment using PET/CT with different tracers
Detailed description
patients with suspected or biopsy proven NET will undergo imaging using a Combination of 18F- FDG , 18F-DOPA and 68Ga-DOTATATE PET/CT before the stat of PRRT . after two cycles of treatment another two PET/CT are done using 18F- FDG and 18F-DOPA and about 6-8 weeks from last treatment the patient will undergo PET/CT using 18F-DOPA .
Interventions
None listed
Sponsors
Sheba Medical Center
Dr. Nayruz Knaana
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patient with neuroendocrine tumor * eligible for PRRT
Exclusion criteria
* younger than 18 years old * pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with good response to Peptide Receptor Radionuclide Therapy (PRRT) | 7 months | patients who have clinical and radiological improvement (using RECIST CRITERIA ) |
| Number of participants with no response to Peptide Receptor Radionuclide Therapy (PRRT) treatment | 7 months | patients who have no clinical and radiological improvement or worsening in clinical condition or radiologic findings (RECIST ) |
Countries
Israel
Contacts
Primary Contactkanana yassin
Backup Contactdomachevsky
Outcome results
None listed